News
ZLAB
15.66
+3.57%
0.54
Weekly Report: what happened at ZLAB last week (0415-0419)?
Weekly Report · 2d ago
Zai Lab files automatic ordinary shares offering
Seeking Alpha · 5d ago
ClearBridge International Growth ACWI Ex-US Strategy Q1 2024 Commentary
Seeking Alpha · 5d ago
A Risky Bet: Zai Lab's Uncertain Future
Seeking Alpha · 04/16 21:08
Weekly Report: what happened at ZLAB last week (0408-0412)?
Weekly Report · 04/15 11:20
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
Zai Lab Limited will report financial results for the first quarter of 2024 and recent corporate updates on May 8, 2024. The Company will host a live conference call and webcast on Thursday, May 9, 2024, at 8:00 a.m. ET. Participants must register in advance of the conference call.
Barchart · 04/15 06:30
ZAI LAB LTD - EXECUTIVES AGREE NOT TO SELL SHARES IN 2024
Reuters · 04/11 11:30
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
Executive Officers of Zai Lab Limited say they do not anticipate selling any shares in the company through the remainder of 2024. Zai lab is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the U.S. The Executive Officers have agreed to stay on the board through 2024.
Barchart · 04/11 06:30
ClearBridge International Growth ADR Strategy Q1 2024 Commentary
Seeking Alpha · 04/10 16:30
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX)
TipRanks · 04/09 10:20
Weekly Report: what happened at ZLAB last week (0401-0405)?
Weekly Report · 04/08 11:25
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
ProfoundBio, A Seattle-Suzhou ADC Biotech, will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. China Medical System in-licensed povorcitinib, an oral JAK1 inhibitor, for autoimmune and inflammatory dermatologic diseases. Shanghai's Visen Pharma announced plans to stage an IPO on the Hong Kong Exchange.
Seeking Alpha · 04/07 10:30
Zai Lab Limited: Report of proposed sale of securities
Press release · 04/04 20:04
Zai Lab reports Krazati lung cancer study meets primary endpoint
Healthcare Zai Lab reports Krazati lung cancer study meets primary endpoint. Bristol Myers’ drug krazati has met its primary endpoint of progression-free survival in lung cancer. Zai plans to submit a market application later this year for Chinese regulatory approval of the drug.
Seeking Alpha · 04/01 14:57
One Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details
Bristol Myers Squibb announces results from first of two studies of Zeposia in Crohn's disease. The study did not meet the primary endpoint of clinical remission at week 12. The company also announced results from a lung cancer study. Krazati is approved for the treatment of patients with a KRASG12C mutation.
Benzinga · 04/01 13:44
BUZZ-Zai Lab up after lung cancer drug meets main goal in late-stage trial
U.S.-listed shares of China-based drug maker Zai Lab Ltd jump 3.3% to $16.55 premarket. Company's drug KRAZATI meets main goal in late-stage study for lung cancer. Drug also met a key secondary goal of the study.
Reuters · 04/01 13:00
ZAI LAB PARTNER BRISTOL MYERS SQUIBB ANNOUNCES PIVOTAL KRYSTAL-12 CONFIRMATORY TRIAL EVALUATING KRAZATI (ADAGRASIB) MEETS PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL FOR PATIENTS WITH PRETREATED KRASG12C-MUTATED LOCALLY ADVANCED OR METASTATIC...
Reuters · 04/01 11:30
ZAI LAB LTD: EXPECTS TO SUBMIT NDA FOR ADAGRASIB TO NMPA FOR KRAS(G12C) MUTATED NSCLC IN SECOND OR LATER LINE TREATMENT IN CHINA THIS YEAR.
Reuters · 04/01 11:30
ZAI LAB LTD: FDA ASSIGNED A PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE OF JUNE 21, 2024
Reuters · 04/01 11:30
Weekly Report: what happened at ZLAB last week (0325-0329)?
Weekly Report · 04/01 11:23
More
Webull provides a variety of real-time ZLAB stock news. You can receive the latest news about Zai Lab Limited through multiple platforms. This information may help you make smarter investment decisions.
About ZLAB
Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.